| Epidemiology of primary biliary cirrhosis | p. 3 |
| Genetic components of primary biliary cirrhosis | p. 13 |
| Infectious aetiology of primary biliary cirrhosis | p. 27 |
| Gender and primary biliary cirrhosis : is microchimerism an aetiological factor? | p. 37 |
| Histology of autoimmune cholestatic liver diseases | p. 47 |
| Mechanisms of biliary epithelial cell apoptosis in primary biliary cirrhosis | p. 56 |
| Role of autoantibodies and autoantigens in primary biliary cirrhosis | p. 69 |
| Clinical aspects and prognosis of primary biliary cirrhosis | p. 79 |
| Pathogenesis of pruritus and fatigue in cholestatic liver disease | p. 94 |
| Is osteoporosis a specific complication of primary biliary cirrhosis? | p. 110 |
| Diseases associated with primary biliary cirrhosis | p. 117 |
| Overlap syndromes, outlier syndromes and changing diagnoses | p. 125 |
| The autoimmune hepatitis/hepatitis C overlap syndrome : does it exist? | p. 132 |
| Histopathology of overlap syndromes in the liver | p. 147 |
| Mechanisms of action of ursodeoxycholic acid in cholestasis | p. 161 |
| Primary biliary cirrhosis : long-term therapy with ursodeoxycholic acid | p. 171 |
| Combination therapy of primary biliary cirrhosis and overlap syndromes | p. 179 |
| Management of pruritus, fatigue and bone disease in patients with primary biliary cirrhosis | p. 188 |
| Liver transplantation, rejection and disease recurrence | p. 197 |
| Primary sclerosing cholangitis : diagnosis and differential diagnosis | p. 203 |
| Incidence and prevalence of primary sclerosing cholangitis around the world | p. 218 |
| Small duct primary sclerosing cholangitis : a separate disease? | p. 225 |
| Prognosis of untreated primary sclerosing cholangitis | p. 231 |
| Is primary sclerosing cholangitis an autoimmune disease? | p. 243 |
| Autoimmune markers and their role in the pathogenesis of primary sclerosing cholangitis | p. 247 |
| The HLA system and other genetic markers in primary sclerosing cholangitis | p. 257 |
| Viruses, protozoans, bacteria and drugs as aetiological factors in primary sclerosing cholangitis | p. 273 |
| Primary sclerosing cholangitis and inflammatory bowell disease : when and how to they relate to each other? | p. 283 |
| Extrahepatic and extraintestinal manifestations of primary sclerosing cholangitis | p. 289 |
| Primary sclerosing cholangitis in paediatrics : what is different? | p. 293 |
| Ursodeoxycholic acid : high-dose, monotherapy or combination therapy? | p. 301 |
| Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis | p. 309 |
| How should and how does antifibrotic therapy act in biliary fibrosis? | p. 314 |
| Ursodeoxycholic acid to prevent colon cancer in primary sclerosing cholangitis | p. 323 |
| Hepatocellular carcinoma, cholangiocarcinoma, colon and pancreatic carcinoma in patients with primary sclerosing cholangitis : epidemiology and risk factors | p. 335 |
| Tumour markers and genetic markers in the diagnosis of bile duct carcinoma | p. 345 |
| Histology and brush cytology for diagnosis of bile duct carcinoma in primary sclerosing cholangitis | p. 354 |
| Primary sclerosing cholangitis : indications for and recurrence after transplantation | p. 364 |
| Table of Contents provided by Blackwell. All Rights Reserved. |
